- li>
- li>
- li>
- li>
- li>
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | -0.23 | 1.04 | -122.57 |
| EPS, GAAP | -0.23 | 1.04 | 1.04 |
| Consensus Estimate | -0.35 | -0.30 | 16.73 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 0.14 | -1.25 | -111.31 |
| EPS, GAAP | 0.17 | -1.25 | -113.48 |
| Consensus Estimate | 0.05 | -1.28 | -104.06 |
| OPTR | Industry Average | |
| P/E (TTM) | 0.00 | NA |
| P/E (Forward) | 0.00 | NA |
| PEG Ratio | 0.00 | 2.17 |
| Price/Sales | 7.83 | 4.18 |
| Beta | 0.78 | 0.62 |
| 5/18/2012 | An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA) (24/7 Wall St) |
| 4/16/2012 | Charting the Market (Barrons.com) |
| 4/10/2012 | CFO Moves: Optimer Pharmaceuticals, ZipRealty, Xenex (WSJ.com) |
| 3/8/2012 | Just the facts, Fool. (The Motley Fool) |
![[sm061210things]](http://s.wsj.net/public/resources/images/PF-AC562_sm0612_C_20120514113337.jpg)
![[sm0612wedding4]](http://s.wsj.net/public/resources/images/PF-AC579_sm0612_C_20120515172853.jpg)
![[sm0612strat]](http://s.wsj.net/public/resources/images/PF-AC580_sm0612_C_20120515180019.jpg)
![[sm0612roi]](http://s.wsj.net/public/resources/images/PF-AC573_sm0612_C_20120515125902.jpg)